MA DM DSc MRCP(UK) FRCR
Friends of ANCHOR Clinical Chair in Oncology
- About
-
- Email Address
- anne.kiltie@abdn.ac.uk
- Office Address
Room 5.053
- School/Department
- School of Medicine, Medical Sciences and Nutrition
Biography
I qualified in medicine from the Universities of Cambridge and Oxford and trained in Clinical Oncology at the Christie Hospital, Manchester, and Cookridge Hospital, Leeds. I undertook my DM at the Paterson Institute, University of Manchester and was a Clinical Research Fellow at ICRF Clare Hall before taking up a Senior Lecturer/Honorary Consultant Clinical Oncologist appointment at the University of Leeds in 2001. I moved to the Department of Oncology, University of Oxford in 2009, and obtained my DSc and personal chair in 2016.
I took up my appointment as Friends of ANCHOR Clinical Chair of Oncology at the University of Aberdeen in June 2021.
My research focusses on exploiting dietary fibre manipulation and its effects on the gut microbiome as an ‘endogenous’ means of radiosensitising tumours without increasing radiation toxicity to the surrounding normal tissues including the intestines.
Qualifications
- DSc Medical Sciences2016 - University of Oxford
- DM Medical Sciences1999 - University of Oxford
- BM BCh Medicine1988 - University of Oxford
- BA Medical Sciences1985 - University of Cambridge
- MRCP(UK) General Medicine1992 - Royal College of Physicians of England
- FRCR Clinical Oncology1995 - Royal College of Radiologists
- MA Medicine1989 - University of Cambridge
- MA Medicine1999 - University of Oxford
Memberships and Affiliations
- Internal Memberships
-
Jul 2021 - present Member of the Rowett Institute Ethics Panel
Oct 2021 - present Member of Friends of ANCHOR Research Advisory Group
Oct 2024 - present Elected member Senatus Academicus
- External Memberships
-
Apr 2024 - present Chair, Scottish Radiation Research Forum (ScoRRF)
Jun 2023 - present Member of RAIDER TrialTranslational Working Group
Jan 2022 - present Member of Scientific Review Group BCAN Bladder Cancer Research Innovation Award 2022
Jan 2022 - present Member of Scottish Radiotherapy Research Forum Committee
Oct 2018 - present Bladder Cancer Advocacy Network (BCAN) Bladder Cancer Research Network Management Committee
Dec 2017 - present Member of Editorial Board of European Urology Oncology
Oct 2016 - present Associate Editor of Bladder Cancer
2014 - present Grant reviewer for Italian Association for Cancer Research (AIRC)
Sept 2012 - present British Uro-oncology Group Executive Committee Trustee
Jan 2012 - present Royal College of Radiologists representative on Advisory Appointments Committees
- Research
-
Research Overview
Tumours in the pelvis, including bladder, prostate and colorectal cancer and gynaecological cancers may be treated by surgical removal or organ-preserving radiotherapy-based treatments. Current organ-preservation standard of care for most tumour sites includes addition of radiosensitising chemotherapy to improve tumour control. However, this often comes at the expense of increased radiotherapy-induced side effects to the surrounding normal tissues, including the intestines. Furthermore, such combined treatments are often not tolerated by elderly patients. With the proportion of over 75-year olds set to double by 2050, there is an urgent need to find alternative approaches to radiosensitisation.
Having worked on histone deacetylase inhibitors, which we showed to be effective tumour radiosensitisers without additional acute and late small intestinal toxicity in in vivo models, we are now working to exploit dietary fibre manipulation and the gut microbiome as an ‘endogenous’ means of radiosensitising tumours without increasing radiation toxicity to the surrounding normal tissues including the intestines.
Research Areas
Applied Health Sciences
Biomedical Sciences
Nutrition and Health
Research Specialisms
- Medicine
- Food Science
- Bacteriology
- Oncology
Our research specialisms are based on the Higher Education Classification of Subjects (HECoS) which is HESA open data, published under the Creative Commons Attribution 4.0 International licence.
- Teaching
-
Teaching Responsibilities
ME3013 MBChB SSC2: supervisor
BM4501 BSc Honours project: supervisor
RN5504 Nutrition and Health through the Life Stages: lecture
RN5505 Clinical Nutrition: lecture and seminar
RN5503 Clinical Nutrition for Disease Prevention: lecture
Non-course Teaching Responsibilities
I am a Regent for the MB ChB Regent Scheme.
- Publications
-
Page 4 of 10 Results 31 to 40 of 96
The National Institute for Health and Care Excellence (NICE) Guidance on Bladder Cancer; a Step in the Right Direction?
Clinical Oncology, vol. 29, no. 6, pp. 344-347Contributions to Journals: Editorials- [ONLINE] DOI: https://doi.org/10.1016/j.clon.2017.01.040
- [ONLINE] View publication in Scopus
Crowdsourcing for translational research: Analysis of biomarker expression using cancer microarrays
British Journal of Cancer, vol. 116, no. 2, pp. 237-245Contributions to Journals: Articles- [ONLINE] DOI: https://doi.org/10.1038/bjc.2016.404
- [ONLINE] View publication in Scopus
Biomarkers of Tumour Radiosensitivity and Predicting Benefit from Radiotherapy
Clinical Oncology, vol. 27, no. 10, pp. 561-569Contributions to Journals: Articles- [ONLINE] DOI: https://doi.org/10.1016/j.clon.2015.06.002
- [ONLINE] View publication in Scopus
Bladder-sparing strategies for invasive bladder cancer
Advances in Bladder Cancer Management. Future Medicine Ltd., pp. 158-173, 16 pagesChapters in Books, Reports and Conference Proceedings: Chapters- [ONLINE] DOI: https://doi.org/10.2217/fmeb2013.13.7
- [ONLINE] View publication in Scopus
Identification of a novel susceptibility locus at 13q34 and refinement of the 20p12.2 region as a multi-signal locus associated with bladder cancer risk in individuals of european ancestry
Human Molecular Genetics, vol. 25, no. 6, pp. 1203-1214Contributions to Journals: Articles- [ONLINE] DOI: https://doi.org/10.1093/hmg/ddv492
- [ONLINE] View publication in Scopus
Treatment of Breast and Prostate Cancer by Hypofractionated Radiotherapy: Potential Risks and Benefits
Clinical Oncology, vol. 27, no. 7, pp. 420-426Contributions to Journals: Articles- [ONLINE] DOI: https://doi.org/10.1016/j.clon.2015.02.008
- [ONLINE] View publication in Scopus
High-throughput DNA sequencing identifies novel CtIP (RBBP8) variants in muscle-invasive bladder cancer patients
Bladder Cancer, vol. 1, no. 1, pp. 31-44Contributions to Journals: Articles- [ONLINE] DOI: https://doi.org/10.3233/BLC-150007
- [ONLINE] View publication in Scopus
Genome-wide association study yields variants at 20p12.2 that associate with urinary bladder cancer
Human Molecular Genetics, vol. 23, no. 20, pp. 5545-5557Contributions to Journals: Articles- [ONLINE] DOI: https://doi.org/10.1093/hmg/ddu264
- [ONLINE] View publication in Scopus
Deoxycytidine kinase expression underpins response to gemcitabine in bladder cancer
Clinical Cancer Research, vol. 20, no. 21, pp. 5435-5445Contributions to Journals: Articles- [ONLINE] DOI: https://doi.org/10.1158/1078-0432.CCR-14-0542
- [ONLINE] View publication in Scopus
Re: Critical analysis of bladder sparing with trimodal therapy in muscle-invasive bladder cancer: A systematic review
European Urology, vol. 66, no. 3, pp. 597-598Contributions to Journals: Comments and Debates- [ONLINE] DOI: https://doi.org/10.1016/j.eururo.2014.06.033
- [ONLINE] View publication in Scopus